Key result
Human NT-proANP assay identifies monkey cardiac disease with ~92% sensitivity.
Why the study?
The clinical utility of ANP as a cardiac biomarker in cynomolgus monkeys is limited by its short half-life and need for immediate proteolysis inhibition.
Does a human NT-proANP assay provide reliable diagnostic utility for cardiac assessment in cynomolgus monkey models?
Cross-Sectional (n=88)
No
Does a human NT-proANP assay provide reliable diagnostic utility for cardiac assessment in cynomolgus monkey models?
A human NT-proANP assay successfully cross-reacts with macaque samples and offers a stable, reliable diagnostic marker for structural and functional cardiac diseases in cynomolgus monkey research models.
Human NT-proANP assay warrants investigation for cardiac diagnosis in monkeys; leaves open prospective validation before adoption.
Atrial natriuretic peptide (ANP) is a well-established biomarker of cardiac disease; however, its clinical utility in cynomolgus monkeys is limited by its short half-life and the requirement for immediate proteolysis inhibition. This study validated a human NT-proANP assay in cynomolgus monkeys to facilitate the use of archived samples for cardiac assessment. We performed in silico amino acid sequence homology analysis and validated the assay using monkey serum and plasma. Stability under various storage conditions was also evaluated. The amino acid sequence of NT-proANP showed high conservation between humans and cynomolgus monkeys. The human NT-proANP assay demonstrated good cross-reactivity and a significant positive correlation with mature ANP levels (R2=0.60). Furthermore, NT-proANP remained detectable for up to 6 h post-collection at room temperature, although a gradual decline was observed. These findings indicate that NT-proANP is a highly useful surrogate marker for ANP in cynomolgus monkeys. This validation expands the potential for retrospective analysis using stored samples, thereby enhancing the value of non-human primate models in cardiovascular research.
No takes yet. Share an insight, caveat, or question.
Nakayama et al. (2026) conducted a cross-sectional in Cardiac disease (n=88). Human NT-proANP assay vs. Healthy animals (no cardiac disease) was evaluated on Diagnostic accuracy of NT-proANP for cardiac disease. A human NT-proANP assay effectively diagnosed cardiac disease in cynomolgus monkeys with a sensitivity of 91.67% and specificity of 83.33% at a cutoff value of 1.79 nmol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: